Take 2: Teva refiles for approval of long-acting schizophrenia drug months after FDA rejection

Teva is taking another run at the FDA approval process. Months after the agency rejected the candidate, Teva has refiled for approval of its long-acting, subcutaneous schizophrenia treatment and talked up its prospects of launching the drug in the first half of next year.